Corbevax effective on kids in phase II, III trials
The Times of India Hyderabad|November 04, 2022
The phase II and III clinical trials of Corbevax for children between five and 18 years have shown the vaccine is safe and fights the Covid-19 infection. The vaccine successfully nullified the effect of both the ancestral strain of Covid-19 from Wuhan and its progeny Delta strain.
Syed.Akbar@timesgroup.com
Corbevax effective on kids in phase II, III trials

Hyderabad: 

The study based on clinical results was published in the latest issue of the scientific journal, Vaccine. Corbevax is India’s first indigenously developed receptor binding domain (RBD) protein sub-unit vaccine for the pandemic virus. It also demonstrated excellent immunogenicity as measured by humoral and cellular immune responses, the study said.

Denne historien er fra November 04, 2022-utgaven av The Times of India Hyderabad.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra November 04, 2022-utgaven av The Times of India Hyderabad.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.